Literature DB >> 33177355

Feasibility and Safety of Laparoscopic Complete Mesocolic Excision (CME) for Right-sided Colon Cancer: Short-term Outcomes. A Randomized Clinical Study.

Giuseppe Di Buono1, Salvatore Buscemi1, Gianfranco Cocorullo1, Vincenzo Sorce1, Giuseppe Amato1, Giulia Bonventre1, Elisa Maienza1, Massimo Galia2, Leonardo Gulotta1, Giorgio Romano1, Antonino Agrusa1.   

Abstract

OBJECTIVE: The aim of this prospective clinical study is to compare short-term outcome of laparoscopic right hemicolectomy using the Complete Mesocolic Excision (CME group) with patients who underwent conventional right-sided colonic resection (NCME group). SUMMARY BACKGROUND DATA: Although CME with central vascular ligation in laparoscopic right hemicolectomy is associated with a significant decrease in local recurrence rates and improvements in cancer-related 5-year survival, there may be additional risks associated with this technique because of increased surgical complications. As a result, there is controversy surrounding its use.
METHODS: In this randomized controlled trial, several primary endpoints (operative time, intraoperative blood loss, other complications, conversion rate, and anastomotic leak) and secondary endpoints (overall postoperative complications) were evaluated. In addition, we evaluated histopathologic data, including specimen length and the number of lymph nodes harvested, as objective signs of the quality of CME, related to oncological outcomes.
RESULTS: The CME group had a significantly longer mean operative time than the NCME group (216.3 minutes vs 191.5 minutes, P = 0.005). However, the CME group had a higher number of lymph nodes (23.8 vs 16.6; P < 0.001) and larger surgical specimens (34.3 cm vs 29.3 cm; P = 0.002). No differences were reported with respect to intraoperative blood loss, conversion rate, leakage, or other postoperative complications.
CONCLUSIONS: In this study laparoscopic CME were a safe and feasible technique with improvement in lymph nodes harvesting and length of surgical specimens with no increase of surgical intraoperative and postoperative complications.
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2021        PMID: 33177355     DOI: 10.1097/SLA.0000000000004557

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  5 in total

Review 1.  Robot-assisted versus laparoscopic short- and long-term outcomes in complete mesocolic excision for right-sided colonic cancer: a systematic review and meta-analysis.

Authors:  Pedja Cuk; Mohamad Jawhara; Issam Al-Najami; Per Helligsø; Andreas Kristian Pedersen; Mark Bremholm Ellebæk
Journal:  Tech Coloproctol       Date:  2022-08-24       Impact factor: 3.699

2.  Analysis of 20 patients with laparoscopic extended right colectomy.

Authors:  Hui-Da Zheng; Jian-Hua Xu; Yu-Rong Liu; Ya-Feng Sun
Journal:  World J Clin Cases       Date:  2022-01-14       Impact factor: 1.337

3.  Automated segmentation by deep learning of loose connective tissue fibers to define safe dissection planes in robot-assisted gastrectomy.

Authors:  Yuta Kumazu; Nao Kobayashi; Naoki Kitamura; Elleuch Rayan; Paul Neculoiu; Toshihiro Misumi; Yudai Hojo; Tatsuro Nakamura; Tsutomu Kumamoto; Yasunori Kurahashi; Yoshinori Ishida; Munetaka Masuda; Hisashi Shinohara
Journal:  Sci Rep       Date:  2021-10-27       Impact factor: 4.379

4.  Totally laparoscopic treatment of intestinal tuberculosis complicated with bowel perforation: The first case report in worldwide literature with a brief review.

Authors:  Giuseppe Di Buono; Roberta Vella; Giuseppe Amato; Giorgio Romano; Vito Rodolico; Marta Saverino; Giovanni De Lisi; Giorgio Romano; Salvatore Buscemi; Antonino Agrusa
Journal:  Front Surg       Date:  2022-08-09

5.  Clinical implication of the advanced lung cancer inflammation index in patients with right-sided colon cancer after complete mesocolic excision: a propensity score-matched analysis.

Authors:  Yu Deng; Yanwu Sun; Yu Lin; Ying Huang; Pan Chi
Journal:  World J Surg Oncol       Date:  2022-08-01       Impact factor: 3.253

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.